论文部分内容阅读
9型前蛋白转化酶枯草杆菌蛋白酶/kexin(PCSK9)抑制药通过抑制低密度脂蛋白受体的降解,发挥重要的调脂作用。在PCSK9抑制药中,PCSK9单克隆抗体是研究最多、疗效最稳定的药物。alirocumab、evolocumab和bococizumab是研究和应用最多的PCSK9单克隆抗体。上述药物在单独使用、和他汀类药物合用以及用于他汀类药物不耐受者、家族性高胆固醇血症等的调脂治疗中发挥重要作用。
Subtype 9 proprotein convertase subtilisin / kexin (PCSK9) inhibitors exert important lipid-lowering effects by inhibiting the degradation of low density lipoprotein receptors. In the PCSK9 inhibitor, PCSK9 monoclonal antibody is the most studied, most stable drug efficacy. alirocumab, evolocumab and bococizumab are the most studied and most commonly used monoclonal antibodies to PCSK9. The above drugs play an important role in the lipid-lowering treatment of single-use, in combination with statins and for statin intolerance, familial hypercholesterolemia and the like.